Cited by 674Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancerHeat shock proteins research

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition

Open access

Shangary, Sanjeev, Qin, Dongguang, McEachern, Donna, Liu, Meilan, Miller, Rebecca S., Qiu, Su, Nikolovska-Coleska, Zaneta, Ding, Ke, Wang, Guoping, Chen, Jianyong, Bernard, Denzil, Zhang, Jian, Lu, Yipin, Gu, Qingyang, Shah, Rajal B., Pienta, Kenneth J., Ling, Xiaolan, Kang, Sanmao, Guo, Ming, Sun, Yi, Yang, Dajun, Wang, Shaomeng·2008·Proceedings of the National Academy of Sciences

DOI 10.1073/pnas.0708917105PMC PMC2268798

Open this paper in CoChat — free account

Abstract

We have designed MI-219 as a potent, highly selective and orally active small-molecule inhibitor of the MDM2–p53 interaction. MI-219 binds to human MDM2 with a K i value of 5 nM and is 10,000-fold selective for MDM2 over MDMX. It disrupts the MDM2–p53 interaction and activates the p53 pathway in cells with wild-type p53, which leads to induction of cell cycle arrest in all cells and selective apoptosis in tumor cells. MI-219 stimulates rapid but transient p53 activation in established tumor xenograft tissues, resulting in inhibition of cell proliferation, induction of apoptosis, and complete tumor growth inhibition. MI-219 activates p53 in normal tissues with minimal p53 accumulation and is not toxic to animals. MI-219 warrants clinical investigation as a new agent for cancer treatment.

Integrity signals

Registry

Crossref · 10.1073/pnas.0708917105

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Surfing the p53 network
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
A System for Stable Expression of Short Interfering RNAs in Mammalian Cells
Brummelkamp, T. R., Bernards, R., & Agami, R. (2002) · Science · doi:10.1126/science.1068999 · Cited by 4,295
Live or let die: the cell's response to p53
Vousden, K. H., & Lü, X. (2002) · Nature reviews. Cancer · doi:10.1038/nrc864 · Cited by 3,231
p53 is required for radiation-induced apoptosis in mouse thymocytes
Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., & Jacks, T. (1993) · Nature · doi:10.1038/362847a0 · Cited by 2,864
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206
WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis.
El‐Deiry, W. S., Harper, J. W., O'Connor, P. M., Velculescu, V. E., Ce, C., Jackman, J., Pietenpol, J. A., Burrell, M., De, H., & Wang, Y. (1994) · PubMed · Cited by 2,021
Restoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820

Flagged first, then by citations

Show all 42 references

Research works printed but not linked: 2

CG Maki, JM Huibregtse, PM Howley Cancer Res 56, 2649–2654 (1996).
WS el-Deiry, JW Harper, PM O'Connor, VE Velculescu, CE Canman, J Jackman, JA Pietenpol, M Burrell, DE Hill, Y Wang, et al. Cancer Res 54, 1169–1174 (1994).

Sorted by citations

Items 201–300 of 674

The role of ubiquitination in health and disease
Liao, Y., Zhang, W., Liu, Y., Zhu, C., & Zou, Z. (2024) · MedComm · doi:10.1002/mco2.736 · Cited by 74
Structure-based design of molecular cancer therapeutics
van Montfort, R. L. M., & Workman, P. (2009) · Trends in biotechnology · doi:10.1016/j.tibtech.2009.02.003 · Cited by 68
In Silico Improvement of β3-Peptide Inhibitors of p53•hDM2 and p53•hDMX
Michel, J., Harker, E. A., Tirado‐Rives, J., Jorgensen, W. L., & Schepartz, A. (2009) · Journal of the American Chemical Society · doi:10.1021/ja901478e · Cited by 69
Oral nano-delivery of anticancer ginsenoside 25-OCH3-PPD, a natural inhibitor of the MDM2 oncogene: Nanoparticle preparation, characterization,in vitroandin vivoanti-prostate cancer activity, and mechanisms of action
Voruganti, S., Qin, J., Sarkar, S., Nag, S. A., Walbi, I. A., Wang, S. F., Zhao, Y., Wang, W., & Zhang, R. (2015) · Oncotarget · doi:10.18632/oncotarget.4091 · Cited by 65
Self-citation
Wild type p53 reactivation: From lab bench to clinic
Selivanova, G. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.03.049 · Cited by 68
Emerging Non-Canonical Functions and Regulation by p53: p53 and Stemness
Olivos, D. J., & Mayo, L. D. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17121982 · Cited by 67
Design of stapled peptide-based PROTACs for MDM2/MDMX atypical degradation and tumor suppression
Chen, S., Li, X., Li, Y., Xing, Y., Geng, C., Gao, S., Li, J., Ma, B., Wang, Z., Lu, W., et al. (2022) · Theranostics · doi:10.7150/thno.75444 · Cited by 64
TP53 in Biology and Treatment of Osteosarcoma
Synoradzki, K. J., Bartnik, E., Czarnecka, A. M., Fiedorowicz, M., Firlej, W., Brodziak, A., Stasinska, A., Rutkowski, P. L., & Grieb, P. (2021) · Cancers · doi:10.3390/cancers13174284 · Cited by 66
Discovery of a Potent and Selective Degrader for USP7
Pei, Y., Fu, J., Shi, Y., Zhang, M., Luo, G., Luo, X., Song, N., Mi, T., Yang, Y., Li, J. X., et al. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202204395 · Cited by 68
Chiral phosphoric acid catalyzed enantioselective 1,3-dipolar cycloaddition reaction of azlactones
Zhang, Z., Sun, W., Zhu, G., Yang, J., Zhang, M., Hong, L., & Wang, R. (2015) · Chemical Communications · doi:10.1039/c5cc08989a · Cited by 62
Assembly of Spirooxindole Derivatives Containing Four Consecutive Stereocenters by Using Cascade Reactions Catalyzed by an N‐Heterocyclic Carbene
Zhou, B. N., Luo, Z., & Li, Y. (2013) · Chemistry - A European Journal · doi:10.1002/chem.201203436 · Cited by 61
Nine-step total synthesis of (−)-strychnofoline
Yu, Q., Guo, P., Jian, J., Chen, Y., & Xu, J. (2018) · Chemical Communications · doi:10.1039/c7cc08938d · Cited by 62
Ensemble-based virtual screening reveals dual-inhibitors for the p53–MDM2/MDMX interactions
Barakat, K., Mane, J. Y., Friesen, D. E., & Tuszyński, J. A. (2009) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2009.12.003 · Cited by 61
Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study
Takahashi, S., Fujiwara, Y., Nakano, K., Shimizu, T., Tomomatsu, J., Koyama, T., Ogura, M., Tachibana, M., Kakurai, Y., Yamashita, T., et al. (2021) · Cancer Science · doi:10.1111/cas.14875 · Cited by 60
Design and synthesis of new bioisosteres of spirooxindoles (MI-63/219) as anti-breast cancer agents
Kumar, A., Gupta, G., Bishnoi, A. K., Saxena, R., Saini, K. S., Konwar, R., Kumar, S., & Dwivedi, A. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.12.037 · Cited by 60
Palladium-catalyzed domino Heck/cyanation: synthesis of 3-cyanomethyloxindoles and their conversion to spirooxoindoles
Jaegli, S., Vors, J., Neuville, L., & Zhu, J. (2010) · Tetrahedron · doi:10.1016/j.tet.2010.09.056 · Cited by 60
Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma
Saha, M. N., Jiang, H., & Chang, H. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.10.6.12535 · Cited by 60
Suberoylanilide hydroxamic acid (SAHA) reverses chemoresistance in head and neck cancer cells by targeting cancer stem cells via the downregulation of nanog
Kumar, B., Yadav, A., Lang, J. C., Teknos, T. N., & Kumar, P. (2015) · Genes & Cancer · doi:10.18632/genesandcancer.54 · Cited by 60
Domino Carbopalladation–Cross-Coupling for the Synthesis of 3,3-Disubstituted Oxindoles
Seashore-Ludlow, B. A., & Somfai, P. (2012) · Organic Letters · doi:10.1021/ol301539p · Cited by 61
Recent Small-Molecule Inhibitors of the p53–MDM2 Protein–Protein Interaction
Beloglazkina, A. A., Zyk, N. V., Majouga, A. G., & Beloglazkina, E. K. (2020) · Molecules · doi:10.3390/molecules25051211 · Cited by 59
Recent in vivo advances of spirocyclic scaffolds for drug discovery
Batista, V. F., Pinto, D. C. G. A., & Silva, A. M. S. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2055544 · Cited by 59
A stapled peptide antagonist of MDM2 carried by polymeric micelles sensitizes glioblastoma to temozolomide treatment through p53 activation
Chen, X., Tai, L., Gao, J., Qian, J., Zhang, M., Li, B., Xie, C., Lu, L., Lu, W., & Lu, W. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.09.061 · Cited by 60
MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner
Feng, F. Y.-C., Zhang, Y., Kothari, V., Evans, J. R., Jackson, W., Chen, W., Johnson, S. B., Luczak, C., Wang, S., & Hamstra, D. A. (2016) · Neoplasia · doi:10.1016/j.neo.2016.01.006 · Cited by 59
Self-citation
Base-Catalyzed Diastereoselective [3 + 3] Annulation of 3-Isothiocyanatooxindoles and Azomethine Imines
Zhu, G., Sun, W., Wu, C., Li, G., Hong, L., & Wang, R. (2013) · Organic Letters · doi:10.1021/ol402295m · Cited by 58
Sorafenib Enhances the Antitumor Effects of Chemoradiation Treatment by Downregulating ERCC-1 and XRCC-1 DNA Repair Proteins
Yadav, A., Kumar, B., Teknos, T. N., & Kumar, P. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0004 · Cited by 58
Assembly of Spirooxindole Derivatives via Organocatalytic Iminium-Enamine Cascade Reactions
Albertshofer, K., Anderson, K. E., & Barbas, C. F. (2012) · Organic Letters · doi:10.1021/ol302876c · Cited by 58
A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML)
Ravandi, F., Gojo, I., Patnaik, M. M., Minden, M. D., Kantarjian, H., Johnson-Levonas, A. O., Fancourt, C., Lam, R., Jones, M. B., Knox, C. D., et al. (2016) · Leukemia Research · doi:10.1016/j.leukres.2016.07.004 · Cited by 57
Asymmetric Construction of Spirocyclic Pyrrolidine-thia(oxa)zolidinediones via N,O-Ligand/Cu(I) Catalyzed 1,3-Dipolar Cycloaddition of Azomethine Ylides with 5-Alkylidene Thia(oxa)zolidine-2,4-diones
Yang, W., Tang, F.-F., He, F., Li, C., Yu, X., & Deng, W. (2015) · Organic Letters · doi:10.1021/acs.orglett.5b02387 · Cited by 57
Reactivation of p53 mutants by p53 reactivation and induction of massive apoptosis in thyroid cancer cells
Messina, R. L., Sanfilippo, M., Vella, V., Pandini, G., Vigneri, P. G., Nicolosi, M. L., Gianì, F., Vigneri, R., & Frasca, F. (2011) · International Journal of Cancer · doi:10.1002/ijc.26228 · Cited by 57
Lewis Acid Catalyzed Unprecedented [3 + 2] Cycloaddition Yields 3,3′-Pyrrolidinyldispirooxindoles Containing Four Contiguous Chiral Stereocenters with Two Contiguous Quaternary Spirostereocenters
Suman, K., Lanka, S., & Thennarasu, S. (2014) · Organic Letters · doi:10.1021/ol501547p · Cited by 57
Targeting the Ubiquitin-Mediated Proteasome Degradation of p53 for Cancer Therapy
DeVine, T., & Dai, M. (2013) · Current Pharmaceutical Design · doi:10.2174/1381612811319180009 · Cited by 58
Modulating Protein-Protein Interactions: From Structural Determinants of Binding to Druggability Prediction to Application
Metz, A., Ciglia, E., & Gohlke, H. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802651553 · Cited by 59
Natural Product MDM2 Inhibitors: Anticancer Activity and Mechanisms of Action
Qin, J., Nag, S. A., Voruganti, S., Wang, W., & Zhang, R. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712803988910 · Cited by 57
Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097
Weisberg, E., Halilovic, E., Cooke, V. G., Nonami, A., Ren, T., Sanda, T., Simkin, I., Yuan, J., Antonakos, B., Barys, L., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0429 · Cited by 56
CircRNA–miRNA networks in regulating bone disease
Huang, W., Wu, Y., Qiao, M., Xie, Z., Cen, X. B., Huang, X., & Zhao, Z. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30625 · Cited by 56
Identification of a new class of natural product MDM2 inhibitor:In vitroandin vivoanti-breast cancer activities and target validation
Qin, J., Wang, W., Voruganti, S., Wang, H., Zhang, W., & Zhang, R. (2014) · Oncotarget · doi:10.18632/oncotarget.3098 · Cited by 56
Computational strategy for intrinsically disordered protein ligand design leads to the discovery of p53 transactivation domain I binding compounds that activate the p53 pathway
Ruan, H., Chen, Y., Niu, X., Zhang, W., Liu, H., Chen, L., Xiong, R., Sun, Q., Jin, C., Liu, Y., et al. (2020) · Chemical Science · doi:10.1039/d0sc04670a · Cited by 57
p53 stabilization induces apoptosis in chronic myeloid leukemia blast crisis cells
Peterson, L. F., Mitrikeska, E., Giannola, D. M., Lui, Y., Sun, H., Bixby, D. L., Malek, S. N., Donato, N. J., Wang, S., & Talpaz, M. (2011) · Leukemia · doi:10.1038/leu.2011.7 · Cited by 55
Self-citation
2-Indolinone a versatile scaffold for treatment of cancer: a patent review (2008–2014)
Leoni, A., Locatelli, A., Morigi, R., & Rambaldi, M. (2015) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2016.1118059 · Cited by 55
Preclinical assessment of JNJ-26854165 (Serdemetan), a novel tryptamine compound with radiosensitizing activity in vitro and in tumor xenografts
Chargari, C., Leteur, C., Angevin, E., Bashir, T., Schoentjes, B., Arts, J., Janicot, M., Bourhis, J., & Deutsch, E. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.08.011 · Cited by 54
Pirh2 RING‐finger E3 ubiquitin ligase: Its role in tumorigenesis and cancer therapy
Jung, Y.-S., Qian, Y., & Chen, X. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.03.052 · Cited by 54
p53-mediated heterochromatin reorganization regulates its cell fate decisions.
Mungamuri, S. K., Benson, E. K., Wang, S., Gu, W., Lee, S. W., & Aaronson, S. A. (2012) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2271 · Cited by 53
Self-citation
P53 activation inhibits all types of hematopoietic progenitors and all stages of megakaryopoiesis
Mahfoudhi, E., Lordier, L., Marty, C., Pan, J., Roy, A., Roy, L., Rameau, P., Abbes, S., Debili, N., Raslova, H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7881 · Cited by 53
Three‐Component Synthesis of Indanone‐Fused Spirooxindole Derivatives
Chen, X., Liu, X., Huang, R., Yan, S., & Lin, J. (2013) · European Journal of Organic Chemistry · doi:10.1002/ejoc.201300376 · Cited by 53
Design, synthesis and biological evaluation of novel potent MDM2/p53 small-molecule inhibitors
Ivanenkov, Y. A., Vasilevski, S. V., Beloglazkina, E. K., Kukushkin, M. E., Machulkin, A. E., Veselov, M. S., Chufarova, N. V., Chernyaginab, E. S., Vanzcool, A. S., Zyk, N. V., et al. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.09.070 · Cited by 53
A novel inhibitor of MDM2 oncogene blocks metastasis of hepatocellular carcinoma and overcomes chemoresistance
Wang, W., Hu, B., Qin, J., Cheng, J., Li, X., Rajaei, M., Fan, J., Yang, X., & Zhang, R. (2019) · Genes & Diseases · doi:10.1016/j.gendis.2019.06.001 · Cited by 53
Elucidation of Acquired Resistance to Bcl-2 and MDM2 Inhibitors in Acute Leukemia In Vitro and In Vivo
Hoffman-Luca, C. G., Ziazadeh, D., McEachern, D., Zhao, Y., Sun, W., Debussche, L., & Wang, S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2506 · Cited by 52
Self-citation
Role of Mdm4 in drug sensitivity of breast cancer cells
Lam, S., Lodder, K., Teunisse, A. F. A. S., Rabelink, M. J. W. E., Schutte, M., & Jochemsen, A. G. (2010) · Oncogene · doi:10.1038/onc.2009.522 · Cited by 52
Li–Fraumeni Syndrome Disease Model: A Platform to Develop Precision Cancer Therapy Targeting Oncogenic p53
Zhou, R., Xu, A., Gingold, J. A., Strong, L. C., Zhao, R., & Lee, D. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.07.004 · Cited by 52
Targeting the ubiquitin–proteasome system to activate wild-type p53 for cancer therapy
Allende-Vega, N., & Saville, M. K. (2009) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2009.10.004 · Cited by 51
Ubiquitylation of p53 by the APC/C inhibitor Trim39
Zhang, L., Huang, N.-J., Chen, C., Tang, W., & Kornbluth, S. A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1212047110 · Cited by 51
Pharmacological activation of the p53 pathway in haematological malignancies
Saha, M. N., Micallef, J., Qiu, L., & Chang, H. (2009) · Journal of Clinical Pathology · doi:10.1136/jcp.2009.070961 · Cited by 51
Targeting MDMX for Cancer Therapy: Rationale, Strategies, and Challenges
Yu, D.-H., Xu, Z., Mo, S., Li, Y., Cheng, X., & Qin, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01389 · Cited by 53
Exploiting the p53 Pathway for TherapyPreprint
Cheok, C. F., & Lane, D. P. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026310 · Cited by 53
Protein–Protein Interactions as Drug Targets
Skwarczynska, M., & Ottmann, C. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.138 · Cited by 52
Highly Stereoselective [4+2] and [3+2] Spiroannulations of 2‐(2‐Oxoindolin‐3‐ylidene)acetic Esters Catalyzed by Bifunctional Thioureas
Monari, M., Montroni, E., Nitti, A., Lombardo, M., Trombini, C., & Quintavalla, A. (2015) · Chemistry - A European Journal · doi:10.1002/chem.201500676 · Cited by 50
Combination therapy in a xenograft model of glioblastoma: Enhancement of the antitumor activity of temozolomide by an MDM2 antagonist
Wang, H., Cai, S., Bailey, B. J., Reza Saadatzadeh, M., Ding, J., Tonsing-Carter, E., Georgiadis, T. M., Zachary Gunter, T., Long, E. C., Minto, R. E., et al. (2017) · Journal of Neurosurgery · doi:10.3171/2016.1.jns152513 · Cited by 49
A Small-Molecule p53 Activator Induces Apoptosis through Inhibiting MDMX Expression in Breast Cancer Cells
Wang, H., & Yan, C. (2011) · Neoplasia · doi:10.1593/neo.11438 · Cited by 50
2-O-Alkylated para-benzamide α-helix mimetics: the role of scaffold curvature
Azzarito, V., Prabhakaran, P., Bartlett, A. I., Murphy, N. S., Hardie, M. J., Kilner, C. A., Edwards, T. A., Warriner, S. L., & Wilson, A. J. (2012) · Organic & Biomolecular Chemistry · doi:10.1039/c2ob26262b · Cited by 49
Stereoselective Construction of Spiro(butyrolactonepyrrolidines) by Highly Efficient Copper(I)/TF‐BiphamPhos‐Catalyzed Asymmetric 1,3‐Dipolar Cycloaddition
Liu, T., He, Z., Tao, H., & Wang, C. (2012) · Chemistry - A European Journal · doi:10.1002/chem.201103876 · Cited by 50
Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas
Künkele, A., Preter, K. D., Heukamp, L. C., Thor, T., Pajtler, K. W., Hartmann, W., Mittelbronn, M. G. A., Grotzer, M. A., Deubzer, H. E., Speleman, F., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos115 · Cited by 49
Nutlins and Ionizing Radiation in Cancer Therapy
Impicciatore, G. G., Sancilio, S., Miscia, S., & Pietro, R. D. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791033932 · Cited by 50
Probing Origin of Binding Difference of inhibitors to MDM2 and MDMX by Polarizable Molecular Dynamics Simulation and QM/MM-GBSA Calculation
Chen, J., Wang, J., Zhang, Q., Chen, K., & Zhu, W. (2015) · Scientific Reports · doi:10.1038/srep17421 · Cited by 49
Self-citation
Regulation of p53 stability as a therapeutic strategy for cancer
Xu, Z., Wu, W., Yan, H., Hu, Y., He, Q., & Luo, P. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114407 · Cited by 52
Network Modeling of MDM2 Inhibitor-Oxaliplatin Combination Reveals Biological Synergy in wt-p53 solid tumors
Azmi, A. S., Banerjee, S., Ali, S., Wang, Z., Bao, B., Beck, F. W. J., Maitah, M., Choi, M., Shields, T. F., Philip, P. A., et al. (2011) · Oncotarget · doi:10.18632/oncotarget.269 · Cited by 48
MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy
Azmi, A. S., Philip, P. A., Beck, F. W., Wang, Z., Banerjee, S., Wang, S., Yang, D., Sarkar, F. H., & Mohammad, R. M. (2010) · Oncogene · doi:10.1038/onc.2010.403 · Cited by 48
Self-citation
Constant Degradation of the Androgen Receptor by MDM2 Conserves Prostate Cancer Stem Cell Integrity
Giridhar, P. V., Williams, K., VonHandorf, A., Deford, P. L., & Kasper, S. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-1753 · Cited by 48
Nutlin-3a Enhances Natural Killer Cell–Mediated Killing of Neuroblastoma by Restoring p53-Dependent Expression of Ligands for NKG2D and DNAM-1 Receptors
Veneziani, I., Infante, P., Ferretti, E., Melaiu, O., Battistelli, C., Lucarini, V., Compagnone, M., Nicoletti, C., Castellano, A., Petrini, S., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0313 · Cited by 48
Cyclin‐dependent kinase 1 inhibitor RO‐3306 enhances p53‐mediated Bax activation and mitochondrial apoptosis in AML
Kojima, K., Shimanuki, M., Shikami, M., Andreeff, M., & Nakakuma, H. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01150.x · Cited by 48
Diastereodivergent construction of bispiro[oxindole-bi-pyrrolidine]s with four consecutive stereocenters via asymmetric [3 + 2] cycloaddition of 2,3-dioxopyrrolidines using identical catalysts
Zhao, X., Xiong, J., An, J., Yu, J., Zhu, L., Feng, X. G., & Jiang, X. (2019) · Organic Chemistry Frontiers · doi:10.1039/c9qo00452a · Cited by 48
MDM2-p53 protein–protein interaction inhibitors: A-ring substituted isoindolinones
Watson, A. F., Liu, J., Bennaceur, K., Drummond, C. J., Endicott, J., Golding, B. T., Griffin, R. J., Haggerty, K., Lü, X., McDonnell, J. M., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.07.084 · Cited by 48
Microwave assisted solid phase synthesis of highly functionalized N-alkylated oligobenzamide α-helix mimetics
Long, K., Edwards, T. A., & Wilson, A. J. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.09.053 · Cited by 49
Formal [3 + 2] cycloaddition of α-unsubstituted isocyanoacetates and methyleneindolinones: enantioselective synthesis of spirooxindoles
Peng, X.-J., Ho, Y. A., Wang, Z., Shao, P., Zhao, Y., & He, Y. (2016) · Organic Chemistry Frontiers · doi:10.1039/c6qo00555a · Cited by 47
Asymmetric Catalytic Double Michael Additions for the Synthesis of Spirooxindoles
Kang, T., Zhao, P., Yang, J., Lin, L., Feng, X., & Liu, X. (2018) · Chemistry - A European Journal · doi:10.1002/chem.201800043 · Cited by 47
Targeting Mitochondrial Proline Dehydrogenase with a Suicide Inhibitor to Exploit Synthetic Lethal Interactions with p53 Upregulation and Glutaminase Inhibition
Scott, G. K., Yau, C. S. F., Becker, B. C., Khateeb, S. I., Mahoney, S. A., Jensen, M. B., Hann, B. C., Cowen, B. J., Pegan, S. D., & Benz, C. C. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1323 · Cited by 47
Discovery of 3-aryl-5-aryl-1,2,4-oxadiazoles as a new series of apoptosis inducers. 2. Identification of more aqueous soluble analogs as potential anticancer agents
Kemnitzer, W. E., Kuemmerle, J., Zhang, H., Kasibhatla, S., Tseng, B., Drewe, J. A., & Cai, S. X. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.05.052 · Cited by 47
Helping the released guardian: Drug combinations for supporting the anticancer activity of HDM2 (MDM2) antagonists
Kocik, J., Machula, M., Wisniewska, A., Surmiak, E., Holak, T. A., & Skalniak, L. (2019) · Cancers · doi:10.3390/cancers11071014 · Cited by 46
Organocatalytic Diastereo‐ and Enantioselective 1,3‐Dipolar Cycloaddition of Azlactones and Methyleneindolinones
Sun, W., Zhu, G., Wu, C., Li, G., Hong, L., & Wang, R. (2013) · Angewandte Chemie · doi:10.1002/ange.201302831 · Cited by 46
Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study
Koyama, T., Shimizu, T., Kojima, Y., Sudo, K., Okuma, H. S., Shimoi, T., Ichikawa, H., Kohsaka, S., Sadachi, R., Hirakawa, A., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0419 · Cited by 46
Ag/P-Stereogenic Phosphine-Catalyzed Enantioselective 1,3-Dipolar Cycloadditions: A Method to Optically Active Pyrrolidines
Zhi, M., Gan, Z., Ma, R., Cui, H., Li, E., Duan, Z., & Mathey, F. (2019) · Organic Letters · doi:10.1021/acs.orglett.9b00926 · Cited by 46
Discovery of AM-7209, a Potent and Selective 4-Amidobenzoic Acid Inhibitor of the MDM2–p53 Interaction
Rew, Y., Sun, D., Yan, X., Beck, H. P., Canon, J. R., Chen, A., Duquette, J., Eksterowicz, J. E., Fox, B. M., Fu, J., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501550p · Cited by 45
Pharmacological inhibition of Mdm2 triggers growth arrest and promotes DNA breakage in mouse colon tumors and human colon cancer cells
Rigatti, M. J., Verma, R., Belinsky, G. S., Rosenberg, D. W., & Giardina, C. A. (2011) · Molecular Carcinogenesis · doi:10.1002/mc.20795 · Cited by 45
1,3-Dipolar cycloaddition enabled isoxazole-fused spiropyrrolidine oxindoles syntheses from 3-methyl-4-nitro-5-alkenyl-isoxazoles and azomethine ylides
Liu, X., Yao, Z., Yang, J., Chen, Z., Liu, X., Zhao, Z., Lu, Y., Zhou, Y., & Cao, Y. (2016) · Tetrahedron · doi:10.1016/j.tet.2016.01.029 · Cited by 45
Self-citation
Chemically Induced Cellular Proteolysis: An Emerging Therapeutic Strategy for Undruggable Targets.
Moon, S., & Lee, B. (2018) · Europe PMC (PubMed Central) · doi:10.14348/molcells.2018.0372 · Cited by 47
Design of ultrahigh-affinity and dual-specificity peptide antagonists of MDM2 and MDMX for P53 activation and tumor suppression
Li, X., Gohain, N., Chen, S., Li, Y., Zhao, X., Li, B., Tolbert, W. D., He, W., Pazgier, M., Hu, H., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.06.010 · Cited by 46
Therapeutic potential of p53 reactivation in prostate cancer: Strategies and opportunities
Kumari, S., Sharma, V., Tiwari, R., Maurya, J. P., Subudhi, B. B., & Senapati, D. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174807 · Cited by 47
Catalytic asymmetric synthesis of 1,2-diamines
Foubelo, F., Nájera, C., Retamosa, M. D. G., Sansano, J. M., & Yus, M. (2024) · Chemical Society Reviews · doi:10.1039/d3cs00379e · Cited by 44
Small molecules that bind the Mdm2 RING stabilize and activate p53
Roxburgh, P., Hock, A. K., Dickens, M. P., Mezna, M., Fischer, P. M., & Vousden, K. H. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs092 · Cited by 43
Organocatalytic Enantioselective Cascade Aza‐Michael/Michael Addition Sequence for Asymmetric Synthesis of Chiral Spiro[pyrrolidine‐3,3′‐oxindole]s
Zhao, B., & Du, D. (2015) · Asian Journal of Organic Chemistry · doi:10.1002/ajoc.201500306 · Cited by 43
Targeting the p53 Pathway in Ewing Sarcoma
Neilsen, P. M., Pishas, K. I., Callen, D. F., & Thomas, D. M. (2010) · Sarcoma · doi:10.1155/2011/746939 · Cited by 43
Tissue‐specific and age‐dependent effects of global Mdm2 loss
Zhang, Y., Xiong, S., Li, Q., Hu, S., Tashakori, M., Pelt, C. V., You, M. J., Pageon, L. R., & Lozano, G. (2014) · The Journal of Pathology · doi:10.1002/path.4368 · Cited by 42
Unprecedented formation of spiro[indoline-3,7′-pyrrolo[1,2-a]azepine] from multicomponent reaction of l -proline, isatin and but-2-ynedioate
Yang, F., Sun, J., Gao, H., & Yan, C. (2015) · RSC Advances · doi:10.1039/c5ra04102c · Cited by 42
Organocatalytic Conjugate Addition of Nitroalkanes to 3-Ylidene Oxindoles: A Stereocontrolled Diversity Oriented Route to Oxindole Derivatives
Quintavalla, A., Lanza, F., Montroni, E., Lombardo, M., & Trombini, C. (2013) · The Journal of Organic Chemistry · doi:10.1021/jo402099p · Cited by 42
Oral delivery of anti-MDM2 inhibitor SP141-loaded FcRn-targeted nanoparticles to treat breast cancer and metastasis
Qin, J., Wang, W., Sarkar, S., & Zhang, R. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.07.008 · Cited by 42
Asymmetric Synthesis of 3,3′-Tetrahydrofuryl Spirooxindoles via Palladium-Catalyzed [3+2] Cycloadditions of Methyleneindolinones with Vinylethylene Carbonates
Wang, J., Zhao, L., Rong, Q., Lv, C. X., Yu, L., Pan, X., Zhao, L., & Hu, L. (2020) · Organic Letters · doi:10.1021/acs.orglett.0c01920 · Cited by 42
Reactivation of p53 by Novel MDM2 Inhibitors: Implications for Pancreatic Cancer Therapy
Azmi, A. S., Philip, P. A., Aboukameel, A., Wang, Z., Banerjee, S., Zafar, S. F., Goustin, A. S., Almhanna, K., Yang, D., Sarkar, F. H., et al. (2010) · Current Cancer Drug Targets · doi:10.2174/156800910791190229 · Cited by 42
Self-citation
S6K1 blockade overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer
Shen, H., Wang, G.-C., Li, X., Ge, X. Q., Wang, M., Shi, Z., Bhardwaj, V., Wang, Z., Zinner, R., Peiper, S. C., et al. (2020) · Oncogene · doi:10.1038/s41388-020-01497-4 · Cited by 41
Self-citation
Diversity-oriented one-pot multicomponent synthesis of spirooxindole derivatives and their biological evaluation for anticancer activities
Yang, J., Liu, X., Wang, D., Tian, M., Han, S.-N., Feng, T., Liu, X., Mei, R., & Zhou, Y. (2016) · Tetrahedron · doi:10.1016/j.tet.2016.10.050 · Cited by 41
Benzyl Isothiocyanate potentiates p53 signaling and antitumor effects against breast cancer through activation of p53-LKB1 and p73-LKB1 axes
Xie, B., Nagalingam, A., Kuppusamy, P., Muniraj, N., Langford, P., Győrffy, B., Saxena, N. K., & Sharma, D. (2017) · Scientific Reports · doi:10.1038/srep40070 · Cited by 41
Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic
Dembla, V., Somaiah, N., Barata, P. C., Hess, K. R., Fu, S., Jankú, F., Karp, D. D., Naing, A., Piha-Paul, S. A., Subbiah, V., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.26075 · Cited by 41

Authors: Shangary, S., Qin, D., McEachern, D., Liu, M., Miller, R. S., Qiu, S., Nikolovska-Coleska, Z., Ding, K., Wang, G., Chen, J., Bernard, D., Zhang, J., Lu, Y., Gu, Q., Shah, R. B., Pienta, K. J., Ling, X., Kang, S., Guo, M., Sun, Y., Yang, D., & Wang, S.
Affiliations: University of Michigan (US)
*Comprehensive Cancer Center and Department of Internal Medicine and
Ascenta Therapeutics, Inc., Malvern, PA 19355
ORCID: McEachern, Donna
Liu, Meilan
Qiu, Su
Ding, Ke
Chen, Jianyong
Bernard, Denzil
Zhang, Jian
Lu, Yipin
Shah, Rajal B.
Pienta, Kenneth J.
Guo, Ming
Sun, Yi
Yang, Dajun
Wang, Shaomeng
Venue: Proceedings of the National Academy of Sciences
Publisher: National Academy of Sciences
Published: 2008-03-11
Volume: 105
Issue: 10
Pages: 3933-3938
ISSN: 0027-8424 (ISSN-L)
1091-6490
DOI: 10.1073/pnas.0708917105
PMC: PMC2268798
OpenAlex: W1992947288
Cited by: 660
References: 42
Citations by year: 2026: 9 · 2025: 9 · 2024: 16 · 2023: 25 · 2022: 23 · 2021: 22 · 2020: 35 · 2019: 34 · 2018: 29 · 2017: 28 · 2016: 42 · 2015: 43 · 2014: 65 · 2013: 45 · 2012: 67
FWCI: 30.50
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Proceedings of the National Academy of Sciences (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Prostate Cancer Foundation (P30CA046592)
Leukemia and Lymphoma Society
National Institutes of Health
National Cancer Institute (R01CA121279, P50CA069568, P30CA046592)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
Keywords: MDM2 inhibitors, p53 activation, p53-MDM2 interaction, selective apoptosis, tumor growth inhibition, tumor xenografts, oral anticancer drugs, cell cycle arrest
MeSH terms: Administration, Oral, Animals, Antineoplastic Agents, Cell Cycle, Humans, Indoles, Models, Molecular, Neoplasms, Protein Binding, Spiro Compounds, Time Factors, Tumor Suppressor Protein p53, Apoptosis, Xenograft Model Antitumor Assays, Cell Line, Tumor, Cell Proliferation, Mice, Proto-Oncogene Proteins c-mdm2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks